<DOC>
	<DOCNO>NCT00583427</DOCNO>
	<brief_summary>The purpose study see medicine call Sulodexide help prevent slow progression Membranoproliferative Glomerulonephritis type II/Dense Deposit Disease . Sulodexide yet FDA approve studied child . Study aim/hypotheses : measure efficacy Sulodexide treatment patient disease/s .</brief_summary>
	<brief_title>Sulodexide Treatment Patients With Dense Deposit Disease</brief_title>
	<detailed_description>Study subject ask take Sulodexide twice day . The Sulodexide take addition regular medication subject . There change medication . The subject also ask blood test month follow kidney function . The frequency test normal/standard frequency person MPGN II/DDD neither increase decrease participation study . The study occur 6 month subject .</detailed_description>
	<mesh_term>Glomerulonephritis , Membranoproliferative</mesh_term>
	<mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
	<criteria>1 . Patients must 5 yr . 20 yr . old 2 . Patients must Membranoproliferative Glomerulonephritis Type II ( MPGN2 ) , also know Dense Deposit Disease ( DDD ) 1 . Patients le 5 year age old 20 year age 2 . Patients DO NOT diagnosis Membranoproliferative Glomerulonephritis ( MPGN 2 ) also know Dense Deposit Disease 3 . Evidence hepatic dysfunction include total bilirubin &gt; 2.0mg/dL ( 34 micromol/L ) liver enzymes &gt; 3 time upper limit normal . 4 . A history major medical condition ( exclude DDD ) , include limited : gastrointestinal bleeding past 3 month ; HIV ; active Hepatitis B C ( current active disease define abnormal liver biopsy persistent , elevated transaminase , SGOT , SGPT ) ; medical condition deem serious investigator 5. risk bleeding , include history bleed diathesis platelet count &lt; 100,000/mm3 6. active cancer 7 . Participation experimental drug study 60 day prior entry study ; plan participate experimental drug study study period . 8 . Known allergy intolerance heparinlike compound 9 . Inability give inform consent cooperate study personnel</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>